NCT07593040 Belzutifan Renal Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines NCT07593040 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 24 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why NCT07593040 is a hot trial to watch
Renal Cell Carcinoma is being segmented by mechanism, treatment setting, geography and endpoint architecture. NCT07593040 is notable because it evaluates Belzutifan in a Phase 2 design sponsored by Vall d'Hebron Institut d'Oncologia. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | NCT07593040 |
| Official title | Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma (Moonlanding) |
| Phase / status | Phase 2 / Not yet recruiting |
| Intervention | Belzutifan |
| Sponsor | Vall d'Hebron Institut d'Oncologia |
| Geography | Spain |
| Enrollment | [object Object] |
| Primary endpoint | Response Rate |
| Endpoint time frame | At 12 weeks from start of treatment |
| Primary completion / readout proxy | [object Object] |
Protocol design and endpoint interpretation
This study is designed to evaluate the efficacy of belzutifan in combination with pembrolizumab with or without lenvatinib in the neoadjuvant setting, followed by adjuvant pembrolizumab versus adjuvant pembrolizumab alone, as treatment for participants with intermediate-high and high risk clear cell renal cell carcinoma (ccRCC).
Allocation is Randomized, masking is None (Open Label), and the intervention model is Crossover Assignment. Planned enrollment of [object Object] participants across Spain shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Response Rate (At 12 weeks from start of treatment) — Radiographic response defined as a decrease of initial tumour size ≥30% from baseline to week 12 CT scan
Readout outlook and evidence gap
The current protocol points to [object Object] as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Belzutifan is indexed as Small molecule drug, with target HIF-2α, mechanism HIF-2α inhibitors, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Vall d'Hebron Institut d'Oncologia is resolved to a normalized organization record in Spain. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
NCT07593040 provides a focused lens on Renal Cell Carcinoma development. Its value will be determined by whether Belzutifan can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
